Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: stockman_scott who wrote (180)	3/18/2002 9:09:17 PM
From: Tomato	Respond to of 544

FWIW, I will look into my TA crystal ball...I see a long trip in your future...(ooops, those were my tarot cards..[g]). Here's what I can tell you based on what I know of TA: askresearch.com 1. Today's action was certainly bullish. Nice volume. 2. One could argue that there was a breakout from congestion and possibly a break of the downtrend that started around 3 months ago in mid-Dec. 3. One could also advise that it might be a decent strategy to wait until the price breaks the recent old highs around 5.80. 4. If you buy it might be a good idea to place a stop loss- always think about an exit strategy before you buy (something I should do more myself).

To: stockman_scott who wrote (180)	3/19/2002 8:20:05 AM
From: JEB	Read Replies (2) \| Respond to of 544

INGN has been on my watch list since I first studied the P53 project. A lot of new discoveries came out of that project including a new philosophy of drug trends for the future by the AMA. Introduction of P53 into the system requires a protein to activate the killer cell activity. To date, the introduction of P53 has given average results so it is more of a gamble to pass FDA muster but it still could. INGN owns a protein in pre-clinical called BAK that destroyed 99.9999999999999% of the breast cancer cells in cell cultures. This is the one I am following.